幹細胞制御研究部
1.

Kano Y, Akutsu M, Mano H, Sato Y, Tsunoda S, Homma Y & Furukawa Y. In vitro
cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonlyused antileukemic agents. Blood 97, 1999-2007 (2001)
https://www.ncbi.nlm.nih.gov/pubmed/11264164/

2.

Ishii H, Inageta T, Mimori K, Saito T, Sasaki H, Isobe M, Mori M, Croce CM, Huebner K,
Ozawa K & Furukawa Y. Frag1, a homolog of alternative replication factor C subunits,links replication stress surveillance with apoptosis. Proc Natl Acad Sci USA 102, 96559660 (2005)
https://www.ncbi.nlm.nih.gov/pubmed/15983387/

3.

Sekiya M, Osuga J, Nagashima S, Ohshiro T, Igarashi M, Okazaki H, Takahashi M,
Tazoe F, Wada T, Ohta K, Takanashi M, Kumagai M, Nishi M, Takase S, Yahagi N,
Yagyu H, Ohashi K, Nagai R, Kadowaki T, Furukawa Y & Ishibashi S. Ablation of neutralcholesterol ester hydrolase 1 accelerates atherosclerosis. Cell Metabolism 10, 219-228(2009)
https://www.ncbi.nlm.nih.gov/pubmed/19723498/

4.

Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T & Furukawa Y. Expression
levels of histone deacetylases determine the cell fate of hematopoietic progenitors. JBiol Chem 284, 30673-30683 (2009)https://www.ncbi.nlm.nih.gov/pubmed/19736310/

5.

Kikuchi J, Wada T, Shimizu R, Izumi T, Akutsu M, Mitsunaga K, Noborio-Hatano K,
Nobuyoshi M, Ozawa K, Kano Y & Furukawa Y. Histone deacetylases are critical targetsof bortezomib-induced cytotoxicity in multiple myeloma. Blood 116, 406-417 (2010)https://www.ncbi.nlm.nih.gov/pubmed/20351311/

6.

Hirose K, Inukai T, Kikuchi J, Furukawa Y, Ikawa T, Kawamoto H, Oram SH, Gottgens B,Kiyokawa N, Miyagawa Y, Okita H, Akahane K, Zhang X, Kuroda I, Honna H, Kagami K,Goi K, Kurosawa H, Look AT, Matsui H, Inaba T & Sugita K. Aberrant induction of LMO2
by the E2A-HLF chimeric transcription factor and Its implication in leukemogenesis of Bprecursor ALL with t(17;19). Blood 11, 962-970 (2010)https://www.ncbi.nlm.nih.gov/pubmed/20519628/

7.

Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y & Furukawa Y. HDAC inhibitors
augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma
cells. Leukemia 24, 1760-1768 (2010)https://www.ncbi.nlm.nih.gov/pubmed/20686505/

8.

Odgerel T, Kikuchi J, Wada T, Shimizu R, Kano Y & Furukawa Y. MSK1 activation inacute myeloid leukemia cells with FLT3 mutations. Leukemia 24, 1087-1090 (2010)https://www.ncbi.nlm.nih.gov/pubmed/20357825/

9.

Wada T, Kikuchi J & Furukawa Y. Histone deacetylase 1 enhances microRNA
processing via deacetylation of DGCR8. EMBO Rep 13, 142-149 (2012)https://www.ncbi.nlm.nih.gov/pubmed/22222205/

10. Azuma M, Koyama D, Kikuchi J, Yoshizawa H, Thasinas D, Shiizaki K, Kuro-o M &Furukawa Y & Kusano E. Promoter methylation confers kidney-specific expression ofthe Klotho gene. FASEB J 26, 4264-4274 (2012)https://www.ncbi.nlm.nih.gov/pubmed/22782974/
11. Kikuchi J, Yamada S, Koyama D, Wada T, Nobuyoshi M, Izumi T, Akutsu M, Kano Y &Furukawa Y. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma
activity in vitro and in vivo by down-regulating the expression of class I histone
deacetylases. J Biol Chem 288, 25593-25602 (2013)https://www.ncbi.nlm.nih.gov/pubmed/23878197/
12. Kuroda I, Inukai T, Zhang X, Kikuchi J, Furukawa Y, Nemoto A, Akahane K, Hirose K,
Honna-Ooshiro H, Goi K, Kagami K, Yagita H, Tauchi T, Maeda Y & Sugita K. BCR-ABL
regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL)
in Philadelphia chromosome-positive leukemia. Oncogene 32, 1670-1681 (2013)https://www.ncbi.nlm.nih.gov/pubmed/22665066/
13. Hiraoka N, Kikuchi J, Koyama D, Wada T, Mori S, Nakamura Y & Furukawa Y. Alkylating
agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediatedglobal histone acetylation and cytotoxicity in mantle cell lymphoma. Blood Cancer J 3,e169 (2013)https://www.ncbi.nlm.nih.gov/pubmed/24335889/14. Koyama D, Kikuchi J, Hiraoka N, Wada T, Kurosawa H, Chiba S & Furukawa Y.
Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional
repression of Notch1 in T-cell acute lymphoblastic leukemia. Leukemia 28, 1216-1226(2014)
https://www.ncbi.nlm.nih.gov/pubmed/24301524/
15. Kikuchi J, Koyama D, Wada T, Izumi T, Hofgaard PO, Bogen B & Furukawa Y.
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple
myeloma. J Clin Invest 125, 4375-4390 (2015)
https://www.ncbi.nlm.nih.gov/pubmed/26517694/
16. Wada T, Koyama D, Kikuchi J, Honda H & Furukawa Y. Overexpression of the shortest
isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant
transformation. Blood 125, 3731-3746 (2015)
https://www.ncbi.nlm.nih.gov/pubmed/25904247/
17. Tago K, Funakoshi-Tago M, Itoh H, Furukawa Y, Kikuchi J, Kato T, Suzuki K &Yanagisawa K. Arf tumor suppressor disrupts the oncogenic positive feedback loop
including c-Myc and DDX5. Oncogene 34, 310-318 (2015)
https://www.ncbi.nlm.nih.gov/pubmed/24469041/
18. Koyama D, Sato Y, Aizawa M, Maki T, Kurosawa M, Kuro-o M & Furukawa Y. Soluble
αKlotho as a candidate for the biomarker of aging. Biochem Biophys Res Commun 467,1019-1025 (2015)
https://www.ncbi.nlm.nih.gov/pubmed/26462468/
19. Kikuchi J, Kuroda Y, Koyama D, Osada N, Izumi T, Yasui H, Ichinohe T & Furukawa Y.
Myeloma cells are activated in bone marrow microenvironment by the CD180/MD-1
complex, which senses lipopolysaccharide. Cancer Res 78, 1766-1778 (2018)https://www.ncbi.nlm.nih.gov/pubmed/29363546/
20. Saito S, Kikuchi J, Koyama D, Sato S, Koyama H, Osada N, Kuroda Y, Akahane K,Inukai T, Umehara T & Furukawa Y. Eradication of central nervous system leukemia ofT-cell origin with a brain-permeable LSD1 inhibitor. Clin Cancer Res 25, 1601-1611(2019)

https://www.ncbi.nlm.nih.gov/pubmed/30518632/